Table 5.
Specific antibody responses to RBD and neutralising antibodies to live SARS-CV-2 post vaccination in phase 2 trial
| Adult group | Elderly group | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Low dose (0, 21 days n = 99) | High dose (0, 21 days n = 100) | low dose (0, 14, 28 days n = 100) | High dose (0, 14, 28 days n = 99) | Placebo (n = 79) | p value | Low dose (0, 21 days n = 99) | High dose (0, 21 days n = 99) | low dose (0, 14, 28 days n = 99) | High dose (0, 14, 28 days n = 98) | Placebo (n = 80) | p value | |
| Day 0 | ||||||||||||
| ELISA antibodies to the receptor binding domain | ||||||||||||
| GMT | 20.0 (20.0–20.0) | 21.1 (19.5–22.9) | 20.0 (20.0–20.0) | 20.4 (19.6–21.1) | 20.7 (19.3–22.2) | 0.44 | 20.0 (20.0–20.0) | 21.1 (19.6–22.7) | 21.0 (19.4–22.8) | 21.8 (19.7–24.1) | 20.4 (19.6–21.2) | 0.49 |
| Neutralising antibodies to live SARS-CoV-2 | ||||||||||||
| GMT | 0.7 (0.7–0.7) | 0.7 (0.7–0.7) | 0.7 (0.7–0.7) | 0.7 (0.7–0.7) | 0.7 (0.7–0.7) | – | 0.7 (0.7–0.7) | 0.7 (0.7–0.7) | 0.7 (0.7–0.7) | 0.7 (0.7–0.7) | 0.7 (0.7–0.7) | – |
| Day 14 | ||||||||||||
| ELISA antibodies to the receptor binding domain | ||||||||||||
| GMT | 32.1 (25.2–41.0) | 93.2 (63.6–136.4) | 105.7 (76.4–146.3) | 601.2 (441.5–818.8) | 20.8 (19.3–22.4) | <0.001 | 21.2 (19.8–22.7) | 38.1 (29.2–49.8) | 44.1 (34.1–57.1) | 198.3 (140.4–280.1) | 21.2 (19.5–23.0) | <0.001 |
| Seroconversion | 15 (25%) | 49 (49%) | 55 (55%) | 89 (89%) | 0 (0%) | <0.001 | 3 (3%) | 20 (20%) | 26 (26%) | 68 (69%) | 1 (1%) | <0.001 |
| Neutralising antibodies to live SARS-CoV-2 | ||||||||||||
| GMT | 1.0 (0.9–1.2) | 2.2 (1.7–2.9) | 3.4 (2.5–4.7) | 25.7 (19.3–34.3) | 0.7 (0.7–0.7) | <0.001 | 1.0 (0.9–1.1) | 1.1 (0.9–1.1) | 1.2 (1.0–1.4) | 7.3 (5.2–10.2) | 0.7 (0.7–0.7) | <0.001 |
| Seroconversion | 7 (7%) | 18 (18%) | 49 (49%) | 91 (92%) | 0 (0%) | <0.001 | 1 (1%) | 4 (4%) | 9 (9%) | 66 (67%) | 0 (0%) | <0.001 |
| Day 30 | ||||||||||||
| ELISA antibodies to the receptor binding domain | ||||||||||||
| GMT | 40.0 (30.6–52.3) | 135.9 (91.9–200.8) | 156.2 (112.1–217.6) | 1099.9 (812.6–1488.7) | 21.8 (19.6–24.2) | <0.001 | 22.5 (20.2–25.1) | 54.4 (39.7–74.7) | 54.3 (40.3–73.3) | 333.2 (232.6–477.3) | 20.8 (19.7–22.1) | <0.001 |
| Seroconversion | 26 (26%) | 57 (58%) | 69 (69%) | 97 (99%) | 1 (1%) | <0.001 | 5 (5%) | 31 (31%) | 33 (34%) | 78 (80%) | 1 (1%) | <0.001 |
| Neutralising antibodies to live SARS-CoV-2 | ||||||||||||
| GMT | 1.9 (1.6–2.4) | 3.6 (2.6–4.9) | 8.1 (5.9–11.2) | 102.6 (75.2–140.1) | 0.7 (0.7–0.7) | <0.001 | 1.3 (1.2–1.5) | 1.6 (1.4–1.9) | 1.7 (1.4–2.1) | 21.3 (13.8–33.1) | 0.7 (0.7–0.7) | <0.001 |
| Seroconversion | 17 (17%) | 37 (37%) | 73 (73%) | 94 (96%) | 0 (0%) | <0.001 | 4 (4%) | 11 (11%) | 18 (18%) | 72 (73%) | 0 (0%) | <0.001 |